
Dendreon (NASDAQ:DNDN) Shares Soar
Shares of Dendreon (NASDAQ:DNDN) gained 16% in late morning trade Monday as investors responded enthusiastically to the biotechnology company’s Q4 results and its announcement it will make its Provenge prostate-cancer treatment commercially available in Germany and the U.K. The company reported a narrower-than-expected Q4 adjusted loss on revenue that was above Street estimates and saw its stock trade at $3.34 with 14.1 million shares changing … Continue reading Dendreon (NASDAQ:DNDN) Shares Soar